NSE · SOTAC · Pharmaceuticals
Sotac Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹101 Cr with net profit ₹8 Cr — a 7.96% net margin, versus 9.61% the period before.
Shareholding
As of 2026-03-31
- Promoter72.85%
- Public10.36%
- FII16.79%
221 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.54× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #69 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,80,131 Cr | 38.63 | 5.75 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,462 Cr | 213.45 | 3.44 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,232 Cr | 20.48 | 4.1 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,705 Cr | 19.46 | 4.93 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,384 Cr | 52.81 | 6.53 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,553 Cr | 432 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,552 Cr | 99.39 | 2.42 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,545 Cr | 294.21 | 5.03 | 16.66% | 15.65% |
| Biocon Ltd. | ₹69,034 Cr | 539.11 | 2.03 | 1.14% | 2.3% |
| Sotac Pharmaceuticals Ltd.(this company) | ₹100 Cr | 215.24 | 1.7 | 9.79% | 4.25% |
AI analysis
AI-generated · google/gemini-2.5-flashSotac Pharmaceuticals Ltd. is listed with a market capitalization of Rs 105 Cr. The company reported revenue of Rs 100.88 Cr and a net profit of Rs 8.0266 Cr for the year ended March 2025. Earnings per share stood at Rs 5.22, with a book value of Rs 53.28.
Positives
- +The promoter holding is high at 72.85% as of March 2026.
- +The profit margin is 424.7%, indicating high profitability.
- +The company has not reported any promoter share pledges.
Negatives
- −Revenue growth for the latest financial year is negative at -6.6%.
- −No quarterly EPS data is provided for the last six quarters.
- −No annual EPS data is provided for the year ending March 2023 and December 2023.
Financial Performance
For the fiscal year ending March 2025, Sotac Pharmaceuticals Ltd. generated revenue of Rs 100.88 Cr. This represents a revenue growth of -6.6% compared to the previous fiscal year. The net profit for the same period was Rs 8.0266 Cr. The company's EPS is Rs 5.22. In the most recent quarter ending June 2024, revenue was Rs 25.25 Cr with a net profit of Rs 1.45 Cr.
Profitability & Returns
Sotac Pharmaceuticals Ltd. achieved a return on equity (ROE) of 9.79% and a return on capital employed (ROCE) of 13.29% for the latest reported period. The profit margin stood at 424.7%. The diluted earnings per share (EPS) for the latest fiscal year is Rs 5.22.
Balance Sheet
The company has a debt-to-equity ratio of 0.7. The book value per share is Rs 53.28.
Ownership & Pledges
The number of shareholders is 221. There are no reported promoter share pledges.
Regulatory & Surveillance
There is no information available regarding the company's inclusion in any surveillance measures.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Sotac Pharmaceuticals Ltd.share price & fundamentals